Amedisys Reports First Quarter 2022 Financial Results and Reaffirms 2022 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Amedisys (AMED) Tops Q1 EPS by 11c; Offers FY22 Guidance
April 27, 2022 4:10 PM EDTAmedisys (NASDAQ: AMED) reported Q1 EPS of $1.23, $0.11 better than the analyst estimate of $1.12. Revenue for the quarter came in at $545.3 million versus the consensus estimate of $558.84 million.
GUIDANCE:
Amedisys sees FY2022 EPS of $5.23-$5.45, versus the consensus of $5.33. Amedisys sees... More
